Vaccination Program for Commercial Layers a
Age | Vaccine | Route | Type |
|---|---|---|---|
1 day | Marek disease | SC | Turkey herpesvirus and SB-1 |
14–21 days | Newcastle/infectious bronchitis | Drinking water | B1/Massachusetts |
Infectious bursal disease | Drinking water | Intermediate | |
5 wk | Newcastle/infectious bronchitis | Drinking water or coarse spray | B1/Massachusetts |
8–10 wk | Newcastle/infectious bronchitis | Drinking water or coarse spray | B1 or LaSota/Massachusetts |
10–12 wk | Encephalomyelitis | Wing web | Live, chick-embryo origin |
Fowlpox | Wing web | Modified live | |
Laryngotracheitis | Intraocular | Modified live | |
10–14 wk | Mycoplasma gallisepticumb | Intraocular or spray | Mild live strain |
or 18 wk | Parenteral | Inactivated | |
12–14 wk | Newcastle/infectious bronchitis | Drinking water or aerosol | B1 or LaSota/Massachusetts |
16–18 wk | Newcastle/infectious bronchitis | Drinking water or aerosol | B1 or LaSota/Massachusetts |
Every 60–90 days or single dose at 18 wk | Newcastle/infectious bronchitis | Parenteral | Inactivated |
a This is an example of a vaccination program. Individual programs are highly variable and reflect local conditions, disease prevalence, severity of the challenge, and individual preferences. | |||
b The use of M gallisepticum vaccine is regulated or prohibited in some states. SB-1 or MDV301 may be combined with turkey herpesvirus in some areas, or Rispens strain may be used in high-challenge areas. Vaccination for infectious bursal disease, laryngotracheitis, and fowlpox depends on local requirements. Other strains of infectious bronchitis (Connecticut, Arkansas 99, Florida 88, etc) are included in some areas. M gallisepticum and Haemophilus gallinarum (coryza) are used only on infected, multiage premises in some areas. | |||